Insider Trading activities of Incyte Corp insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Incyte Corp since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Incyte Corp since year 2005. Table 2 shows the detailed insider transactions of Incyte Corp since 2005. The reporting company's ticker symbol is INCY. The reporting company's CIK number is 879169.
The total value of stock buying since 2005 is $313,711,766.
The total value of stock sales since 2005 is $508,189,439.
The total value of stock option exercises since 2005 is $88,892,729.


 1   2   3 
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Incyte Corp (INCY).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-11 0 $0 3,915 $413,541 0 $0
2017-09 100,000 $13,200,000 76,036 $9,175,475 4,820 $170,851
2017-08 0 $0 26,931 $3,681,539 26,931 $715,422
2017-07 0 $0 11,305 $1,458,342 11,305 $750,759
2017-06 0 $0 32,058 $3,900,938 33,350 $2,441,811
2017-05 1,000 $123,400 18,693 $2,274,877 6,884 $270,831
2017-04 2,500 $341,270 78,960 $10,882,848 138,960 $6,432,174
2017-03 0 $0 70,000 $10,391,163 70,000 $1,061,199
2017-02 0 $0 52,008 $6,280,815 50,000 $916,000
2017-01 0 $0 11,739 $1,332,963 0 $0
2016-11 0 $0 12,715 $1,331,114 10,000 $147,200
2016-10 0 $0 45,913 $4,376,535 45,913 $1,534,149
2016-09 0 $0 20,000 $1,800,000 20,000 $294,400
2016-08 0 $0 10,000 $879,599 0 $0
2016-07 0 $0 60,000 $5,400,000 60,000 $883,200
2016-04 0 $0 0 $0 20,000 $77,200
2016-03 800,000 $50,975,199 0 $0 60,000 $231,600
2016-02 0 $0 0 $0 5,377 $98,506
2016-01 0 $0 17,468 $1,442,367 19,977 $160,170
2015-12 0 $0 5,873 $627,040 5,873 $107,592
2015-11 0 $0 236,944 $27,043,013 236,158 $4,204,514
2015-10 0 $0 6,159 $706,965 6,159 $112,832
2015-09 0 $0 20,460 $2,560,532 4,640,085 $296,032
2015-08 0 $0 6,158 $679,922 14,555 $264,421
2015-07 0 $0 89,226 $10,599,277 89,226 $1,566,494
2015-06 0 $0 37,851 $4,083,575 37,851 $808,016
2015-05 0 $0 320,721 $34,441,206 400,721 $5,543,119
2015-04 0 $0 130,813 $12,726,592 118,692 $2,274,114
2015-03 0 $0 326,094 $29,904,008 330,498 $4,481,352
2015-02 0 $0 218,945 $16,679,872 98,945 $1,294,748
2015-01 0 $0 112,277 $8,380,226 112,277 $1,433,581
2014-12 0 $0 73,113 $5,439,818 29,607 $428,747
2014-11 0 $0 208,764 $14,263,011 226,724 $2,587,040
2014-10 0 $0 19,111 $986,567 33,015 $351,965
2014-09 0 $0 19,111 $910,079 19,111 $308,724
2014-08 0 $0 19,111 $993,087 19,111 $308,724
2014-07 0 $0 19,111 $924,527 19,111 $308,724
2014-06 0 $0 219,111 $11,601,714 219,111 $2,102,061
2014-05 0 $0 55,169 $2,807,933 83,111 $839,264
2014-04 0 $0 30,555 $1,457,779 55,555 $700,648
2014-02 0 $0 1,900,306 $125,384,150 1,899,119 $18,985,073
2013-12 0 $0 0 $0 45,000 $329,400
2013-11 0 $0 50,000 $2,368,500 0 $0
2013-09 0 $0 697,045 $25,412,623 694,011 $5,964,873
2013-08 0 $0 50,000 $1,335,000 0 $0
2013-06 0 $0 0 $0 30,000 $133,200
2013-05 0 $0 95,699 $2,165,286 83,700 $718,403
2013-04 0 $0 0 $0 10,000 $44,400
2013-03 0 $0 20,000 $476,399 0 $0
2013-02 0 $0 381,723 $8,451,213 361,723 $2,963,152
2012-12 45,000 $724,950 50,000 $801,500 0 $0
2012-08 0 $0 0 $0 10,000 $56,700
2012-07 0 $0 72,366 $1,782,088 107,552 $757,918
2012-06 0 $0 0 $0 5,000 $33,300
2012-05 0 $0 468,846 $10,707,565 439,055 $3,434,892
2012-04 0 $0 30,000 $688,500 30,000 $261,690
2012-03 0 $0 0 $0 50,000 $177,980
2012-02 0 $0 20,000 $350,600 0 $0
2012-01 1,151,103 $18,939,868 0 $0 65,000 $396,500
2011-12 5,256,687 $72,683,575 0 $0 0 $0
2011-11 2,683,593 $33,404,471 0 $0 0 $0
2011-06 0 $0 160,000 $2,879,809 140,000 $730,400
2011-05 0 $0 220,343 $4,368,634 175,000 $1,615,500
2011-04 0 $0 235,000 $3,977,085 225,000 $1,052,250
2011-03 0 $0 220,000 $3,143,930 230,834 $2,286,054
2011-02 0 $0 50,000 $717,500 70,000 $471,300
2011-01 0 $0 40,310 $638,228 40,310 $249,518
2010-12 0 $0 20,000 $341,090 0 $0
2010-11 0 $0 11,000 $176,000 0 $0
2010-10 0 $0 34,253 $581,768 0 $0
2010-09 0 $0 2,602,950 $38,723,880 0 $0
2010-08 0 $0 1,287,743 $18,093,024 94,960 $584,004
2010-07 12,000 $124,730 0 $0 25,142 $157,766
2010-06 0 $0 97,917 $1,287,608 97,917 $599,252
2010-03 0 $0 20,000 $258,800 20,000 $83,800
2010-01 0 $0 22,000 $239,800 0 $0
2009-03 120,486 $259,153 0 $0 0 $0
2008-12 1,752,008 $6,126,417 0 $0 0 $0
2008-11 32,500 $81,213 0 $0 0 $0
2008-10 10,000 $49,500 0 $0 0 $0
2008-07 2,195,003 $19,755,027 0 $0 0 $0
2008-01 3,332,905 $33,599,079 0 $0 0 $0
2007-12 1,892,605 $18,982,674 0 $0 0 $0
2007-11 4,709,180 $38,597,583 0 $0 70,000 $297,220
2007-08 1,122,751 $5,517,034 0 $0 0 $0
2006-04 18,000 $66,135 0 $0 0 $0
2005-08 2,700 $19,548 0 $0 0 $0
2005-03 20,000 $140,940 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Incyte Corp insiders (INCY)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-11-02 Gryska David W (Executive Vice President, CFO) Sale 3,915 105.63 413,541
2017-09-18 Hoppenot Herve (Chairman / CEO) Sale 70,502 119.45 8,421,463
2017-09-14 Flannelly Barry P (EVP & General Manager US) Sale 714 124.25 88,714
2017-09-08 Baker Brothers Life Sciences Lp (Director) Buy 100,000 132.00 13,200,000
2017-09-05 Trower Paul (Principal Accounting Officer) Sale 3,000 138.41 415,230
2017-09-05 Trower Paul (Principal Accounting Officer) Option Ex 3,000 17.79 53,370
2017-09-01 Siegel Eric H. (EVP, General Counsel) Sale 1,820 137.40 250,068
2017-09-01 Siegel Eric H. (EVP, General Counsel) Option Ex 1,820 64.55 117,481
2017-08-31 Swain Paula J (EVP, Human Resources) Sale 20,000 140.00 2,800,000
2017-08-31 Swain Paula J (EVP, Human Resources) Option Ex 20,000 17.79 355,800
2017-08-29 Stein Steven H (EVP & Chief Medical Officer) Sale 2,111 125.00 263,875
2017-08-29 Stein Steven H (EVP & Chief Medical Officer) Option Ex 2,111 89.42 188,771
2017-08-04 Trower Paul (Principal Accounting Officer) Sale 3,000 125.25 375,750
2017-08-04 Trower Paul (Principal Accounting Officer) Option Ex 3,000 17.79 53,370
2017-08-01 Siegel Eric H. (EVP, General Counsel) Sale 1,820 132.92 241,914
2017-08-01 Siegel Eric H. (EVP, General Counsel) Option Ex 1,820 64.55 117,481
2017-07-20 Stein Steven H (EVP & Chief Medical Officer) Sale 6,485 131.09 850,118
2017-07-20 Stein Steven H (EVP & Chief Medical Officer) Option Ex 6,485 89.42 579,908
2017-07-05 Trower Paul (Principal Accounting Officer) Sale 3,000 126.18 378,540
2017-07-05 Trower Paul (Principal Accounting Officer) Option Ex 3,000 17.79 53,370
2017-07-03 Siegel Eric H. (EVP, General Counsel) Sale 1,820 126.20 229,684
2017-07-03 Siegel Eric H. (EVP, General Counsel) Option Ex 1,820 64.55 117,481
2017-06-30 Gryska David W (Executive Vice President, CFO) Sale 599 129.74 77,714
2017-06-30 Gryska David W (Executive Vice President, CFO) Option Ex 599 73.21 43,852
2017-06-20 Stein Steven H (EVP & Chief Medical Officer) Sale 9,883 125.00 1,235,375
2017-06-20 Stein Steven H (EVP & Chief Medical Officer) Option Ex 9,883 92.22 911,410
2017-06-12 Gryska David W (Executive Vice President, CFO) Sale 16,756 116.60 1,953,749
2017-06-12 Gryska David W (Executive Vice President, CFO) Option Ex 16,756 73.21 1,226,706
2017-06-06 Siegel Eric H. (EVP, General Counsel) Option Ex 1,292 68.88 88,992
2017-06-05 Trower Paul (Principal Accounting Officer) Sale 3,000 132.50 397,500
2017-06-05 Trower Paul (Principal Accounting Officer) Option Ex 3,000 17.79 53,370
2017-06-01 Siegel Eric H. (EVP, General Counsel) Sale 1,820 130.00 236,600
2017-06-01 Siegel Eric H. (EVP, General Counsel) Option Ex 1,820 64.55 117,481
2017-05-31 Bienaime Jean Jacques (Director) Buy 500 131.80 65,900
2017-05-15 Bienaime Jean Jacques (Director) Buy 500 115.00 57,500
2017-05-08 Huber Reid M (EVP, Chief Scientific Officer) Sale 8,577 119.21 1,022,464
2017-05-05 Trower Paul (Principal Accounting Officer) Sale 3,000 121.70 365,100
2017-05-05 Trower Paul (Principal Accounting Officer) Option Ex 3,000 17.79 53,370
2017-05-01 Flannelly Barry P (EVP & General Manager US) Sale 5,296 124.68 660,305
2017-05-01 Flannelly Barry P (EVP & General Manager US) Option Ex 2,064 48.44 99,980
2017-05-01 Siegel Eric H. (EVP, General Counsel) Sale 1,820 124.73 227,008
2017-05-01 Siegel Eric H. (EVP, General Counsel) Option Ex 1,820 64.55 117,481
2017-04-28 Bienaime Jean Jacques (Director) Buy 500 124.26 62,130
2017-04-28 Gryska David W (Executive Vice President, CFO) Sale 1,389 124.26 172,597
2017-04-28 Gryska David W (Executive Vice President, CFO) Option Ex 1,389 67.06 93,146
2017-04-27 Baker Brothers Life Sciences Lp (Director) Option Ex 60,000 7.26 435,600
2017-04-13 Bienaime Jean Jacques (Director) Buy 1,000 139.66 139,660
2017-04-10 Siegel Eric H. (EVP, General Counsel) Sale 4,043 140.18 566,747
2017-04-10 Siegel Eric H. (EVP, General Counsel) Option Ex 4,043 41.44 167,521
2017-04-10 Gryska David W (Executive Vice President, CFO) Sale 41,528 138.00 5,730,864
2017-04-10 Gryska David W (Executive Vice President, CFO) Option Ex 41,528 67.06 2,784,867
2017-04-07 Stein Steven H (EVP & Chief Medical Officer) Sale 32,000 137.90 4,412,640
2017-04-07 Stein Steven H (EVP & Chief Medical Officer) Option Ex 32,000 92.22 2,951,040
2017-04-07 Bienaime Jean Jacques (Director) Buy 1,000 139.48 139,480
2017-03-17 Friedman Paul A (Director) Sale 41,693 148.18 6,178,068
2017-03-17 Friedman Paul A (Director) Option Ex 41,693 18.32 763,815
2017-03-17 Brooke Paul A (Director) Sale 20,000 147.75 2,955,000
2017-03-17 Brooke Paul A (Director) Option Ex 20,000 7.26 145,200
2017-03-16 Friedman Paul A (Director) Sale 8,307 151.45 1,258,095
2017-03-16 Friedman Paul A (Director) Option Ex 8,307 18.32 152,184
2017-02-27 Huber Reid M (EVP, Chief Scientific Officer) Sale 2,008 131.88 264,815
2017-02-23 Friedman Paul A (Director) Sale 50,000 120.32 6,016,000
2017-02-23 Friedman Paul A (Director) Option Ex 50,000 18.32 916,000
2017-01-09 Huber Reid M (EVP, Chief Scientific Officer) Sale 11,739 113.55 1,332,963
2016-11-15 Swain Paula J (EVP, Human Resources) Sale 10,000 103.26 1,032,600
2016-11-15 Swain Paula J (EVP, Human Resources) Option Ex 10,000 14.72 147,200
2016-11-09 Huber Reid M (EVP, Chief Scientific Officer) Sale 2,715 109.95 298,514
2016-10-20 Swain Paula J (EVP, Human Resources) Sale 10,000 90.00 900,000
2016-10-20 Swain Paula J (EVP, Human Resources) Option Ex 10,000 14.72 147,200
2016-10-07 Flannelly Barry P (EVP & General Manager US) Sale 24,204 97.00 2,347,788
2016-10-07 Flannelly Barry P (EVP & General Manager US) Option Ex 24,204 48.44 1,172,441
2016-10-07 Huber Reid M (EVP, Chief Scientific Officer) Sale 11,709 96.40 1,128,747
2016-10-07 Huber Reid M (EVP, Chief Scientific Officer) Option Ex 11,709 18.32 214,508
2016-09-23 Swain Paula J (EVP, Human Resources) Sale 20,000 90.00 1,800,000
2016-09-23 Swain Paula J (EVP, Human Resources) Option Ex 20,000 14.72 294,400
2016-08-02 Huber Reid M (EVP, Chief Scientific Officer) Sale 10,000 87.96 879,599
2016-07-29 Swain Paula J (EVP, Human Resources) Sale 60,000 90.00 5,400,000
2016-07-29 Swain Paula J (EVP, Human Resources) Option Ex 60,000 14.72 883,200
2016-04-01 Brooke Paul A (Director) Option Ex 20,000 3.86 77,200
2016-03-17 Baker Bros. Advisors (gp) Llc (Director) Buy 400,000 61.36 24,543,600
2016-03-17 Baker Bros. Advisors (gp) Llc (Director) Option Ex 60,000 3.86 231,600
2016-03-15 Baker Bros. Advisors (gp) Llc (Director) Buy 400,000 66.08 26,431,599
2016-02-16 Huber Reid M (EVP, Chief Scientific Officer) Option Ex 5,377 18.32 98,506
2016-01-15 Siegel Eric H. (EVP, General Counsel) Option Ex 2,509 18.32 45,964
2016-01-15 Swain Paula J (EVP, Human Resources) Sale 13,531 76.96 1,041,345
2016-01-15 Swain Paula J (EVP, Human Resources) Option Ex 13,531 3.11 42,081
2016-01-06 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,937 101.86 401,022
2016-01-06 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,937 18.32 72,125
2015-12-10 Siegel Eric H. (EVP, General Counsel) Sale 1,936 107.96 209,010
2015-12-10 Siegel Eric H. (EVP, General Counsel) Option Ex 1,936 18.32 35,467
2015-12-07 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,937 106.18 418,030
2015-12-07 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,937 18.32 72,125
2015-11-18 Friedman Paul A (Director) Sale 125,000 115.27 14,408,750
2015-11-18 Friedman Paul A (Director) Option Ex 125,000 17.79 2,223,750
2015-11-17 Friedman Paul A (Director) Sale 100,000 112.20 11,220,300
2015-11-17 Friedman Paul A (Director) Option Ex 100,000 17.79 1,779,000
2015-11-10 Siegel Eric H. (EVP, General Counsel) Sale 2,222 104.86 232,998
2015-11-10 Siegel Eric H. (EVP, General Counsel) Option Ex 2,222 18.32 40,707
2015-11-06 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,936 116.51 458,583
2015-11-06 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,936 18.32 72,107
2015-11-03 Wenqing Yao (EVP, Discovery Medicinal and P) Sale 5,786 124.85 722,382
2015-11-03 Wenqing Yao (EVP, Discovery Medicinal and P) Option Ex 5,000 17.79 88,950
2015-10-13 Siegel Eric H. (EVP, General Counsel) Sale 2,222 101.49 225,510
2015-10-13 Siegel Eric H. (EVP, General Counsel) Option Ex 2,222 18.32 40,707
2015-10-06 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,937 122.29 481,455
2015-10-06 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,937 18.32 72,125
2015-09-21 Huber Reid M (EVP, Chief Scientific Officer) Sale 10,000 124.29 1,242,900
2015-09-21 Huber Reid M (EVP, Chief Scientific Officer) Option Ex 10,000 18.32 183,200
2015-09-16 Baker Bros. Advisors (gp) Llc (Director) Option Ex 4,623,926 .00 0
2015-09-16 Siegel Eric H. (EVP, General Counsel) Sale 2,222 130.69 290,393
2015-09-16 Siegel Eric H. (EVP, General Counsel) Option Ex 2,222 18.32 40,707
2015-09-11 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 4,301 130.00 559,130
2015-09-08 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,937 118.90 468,109
2015-09-08 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,937 18.32 72,125
2015-08-13 Siegel Eric H. (EVP, General Counsel) Sale 2,222 107.69 239,287
2015-08-13 Siegel Eric H. (EVP, General Counsel) Option Ex 2,222 18.32 40,707
2015-08-07 Huber Reid M (EVP, Chief Scientific Officer) Option Ex 8,397 18.05 151,607
2015-08-06 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,936 111.95 440,635
2015-08-06 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,936 18.32 72,107
2015-07-15 Wenqing Yao (EVP, Discovery Medicinal and P) Sale 5,000 119.75 598,750
2015-07-15 Wenqing Yao (EVP, Discovery Medicinal and P) Option Ex 5,000 17.79 88,950
2015-07-15 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 70,217 120.00 8,426,040
2015-07-15 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 70,217 17.79 1,249,160
2015-07-14 Wenqing Yao (EVP, Discovery Medicinal and P) Sale 7,850 114.75 900,787
2015-07-14 Wenqing Yao (EVP, Discovery Medicinal and P) Option Ex 7,850 14.72 115,552
2015-07-14 Siegel Eric H. (EVP, General Counsel) Sale 2,222 113.61 252,441
2015-07-14 Siegel Eric H. (EVP, General Counsel) Option Ex 2,222 18.32 40,707
2015-07-06 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,937 107.00 421,259
2015-07-06 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,937 18.32 72,125
2015-06-23 Daly James M (EVP, Chief Commercial Officer) Sale 11,691 108.06 1,263,329
2015-06-23 Daly James M (EVP, Chief Commercial Officer) Option Ex 11,691 29.03 339,366
2015-06-19 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 20,000 108.13 2,162,600
2015-06-19 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 20,000 17.79 355,800
2015-06-12 Siegel Eric H. (EVP, General Counsel) Sale 2,223 105.31 234,104
2015-06-12 Siegel Eric H. (EVP, General Counsel) Option Ex 2,223 18.32 40,725
2015-06-08 Levy Richard S (EVP, Chief Drug Dev Officer) Sale 3,937 107.58 423,542
2015-06-08 Levy Richard S (EVP, Chief Drug Dev Officer) Option Ex 3,937 18.32 72,125
2015-05-27 Friedman Paul A (Director) Sale 69,132 107.42 7,426,505
2015-05-27 Friedman Paul A (Director) Option Ex 69,132 14.72 1,017,623
2015-05-26 Daly James M (EVP, Chief Commercial Officer) Sale 12,093 106.22 1,284,457
2015-05-26 Daly James M (EVP, Chief Commercial Officer) Option Ex 12,093 29.03 351,035
2015-05-26 Friedman Paul A (Director) Sale 127,619 107.27 13,689,434
2015-05-26 Friedman Paul A (Director) Option Ex 127,619 14.72 1,878,551
2015-05-22 Friedman Paul A (Director) Sale 79,592 108.12 8,605,327
2015-05-22 Friedman Paul A (Director) Option Ex 79,592 14.72 1,171,594
2015-05-21 Friedman Paul A (Director) Sale 22,651 108.83 2,465,221
2015-05-21 Friedman Paul A (Director) Option Ex 22,651 14.72 333,422
2015-05-18 Brooke Paul A (Director) Option Ex 20,000 7.68 153,600
2015-05-14 Siegel Eric H. (EVP, General Counsel) Sale 2,222 104.99 233,287
2015-05-14 Siegel Eric H. (EVP, General Counsel) Option Ex 2,222 18.32 40,707
 1   2   3 

Insider trading activities including stock purchases, stock sales, and option exercises of INCY listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Incyte Corp (symbol INCY, CIK number 879169) see the Securities and Exchange Commission (SEC) website.